BGLC vs QDEL vs BIO vs IDXX vs TMO

For growth investors, IDEXX Laboratories, Inc.

(IDXX) is the stronger pick with 10. 4% revenue growth year-over-year, versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). Bio-Rad Laboratories, Inc. (BIO) offers the better valuation at 9. 2x trailing P/E (27. 4x forward), making it the more compelling value choice. Analysts rate QuidelOrtho Corporation (QDEL) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Bio-Rad Laboratories, Inc.

(BIO) is the cheapest at 9. 2x versus IDEXX Laboratories, Inc. at 43. 7x. On forward P/E, QuidelOrtho Corporation is actually cheaper at 6. 4x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: IDEXX Laboratories, Inc. wins at 2. 68x versus Thermo Fisher Scientific Inc. 's 8. 86x.

Over the past 5 years, IDEXX Laboratories, Inc.

(IDXX) delivered a total return of +5. 1%, compared to -98. 6% for BioNexus Gene Lab Corp. (BGLC). Over 10 years, the gap is even starker: IDXX returned +542. 3% versus BGLC's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bio-Rad Laboratories, Inc.

(BIO) is the lower-risk stock at 0. 91β versus QuidelOrtho Corporation's 2. 28β — meaning QDEL is approximately 150% more volatile than BIO relative to the S&P 500. On balance sheet safety, BioNexus Gene Lab Corp. (BGLC) carries a lower debt/equity ratio of 3% versus 146% for QuidelOrtho Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), IDEXX Laboratories, Inc.

(IDXX) is pulling ahead at 10. 4% versus -2. 7% for BioNexus Gene Lab Corp. (BGLC). On earnings-per-share growth, the picture is similar: Bio-Rad Laboratories, Inc. grew EPS 142. 6% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, IDXX leads at 8. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bio-Rad Laboratories, Inc.

(BIO) is the more profitable company, earning 29. 4% net margin versus -41. 5% for QuidelOrtho Corporation — meaning it keeps 29. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IDXX leads at 31. 6% versus -33. 7% for QDEL. At the gross margin level — before operating expenses — IDXX leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, IDEXX Laboratories, Inc. (IDXX) is the more undervalued stock at a PEG of 2. 68x versus Thermo Fisher Scientific Inc. 's 8. 86x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, QuidelOrtho Corporation (QDEL) trades at 6. 4x forward P/E versus 38. 3x for IDEXX Laboratories, Inc. — 31. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for QDEL: 57. 8% to $17. 00.

In this comparison, TMO (0.

4% yield) pays a dividend. BGLC, QDEL, BIO, IDXX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Bio-Rad Laboratories, Inc.

(BIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 91)). QuidelOrtho Corporation (QDEL) carries a higher beta of 2. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BIO: +79. 3%, QDEL: -34. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BGLC is a small-cap quality compounder stock; QDEL is a small-cap quality compounder stock; BIO is a small-cap deep-value stock; IDXX is a mid-cap quality compounder stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.